Pamidronate disodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for pamidronate disodium and what is the scope of freedom to operate?
Pamidronate disodium
is the generic ingredient in two branded drugs marketed by Novartis, Aesgen, Am Regent, Areva Pharms, Dr Reddys, Fresenius Kabi Usa, Hikma, Hospira, Mn Pharms, Mylan Labs Ltd, Sagent Pharms Inc, Sun Pharma Global, and Teva Pharms Usa, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.Two suppliers are listed for this compound.
Summary for pamidronate disodium
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 13 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 159 |
Clinical Trials: | 8 |
Patent Applications: | 7,439 |
What excipients (inactive ingredients) are in pamidronate disodium? | pamidronate disodium excipients list |
DailyMed Link: | pamidronate disodium at DailyMed |
Recent Clinical Trials for pamidronate disodium
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Peking Union Medical College Hospital | Phase 1 |
The Hospital for Sick Children | N/A |
National Cancer Institute (NCI) | Phase 1 |
Pharmacology for pamidronate disodium
Drug Class | Bisphosphonate |
US Patents and Regulatory Information for pamidronate disodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 076207-001 | May 17, 2002 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Fresenius Kabi Usa | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 075773-001 | May 6, 2002 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Aesgen | PAMIDRONATE DISODIUM | pamidronate disodium | INJECTABLE;INJECTION | 075594-001 | May 6, 2002 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for pamidronate disodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-004 | May 6, 1993 | ⤷ Subscribe | ⤷ Subscribe |
Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-001 | Oct 31, 1991 | ⤷ Subscribe | ⤷ Subscribe |
Novartis | AREDIA | pamidronate disodium | INJECTABLE;INJECTION | 020036-004 | May 6, 1993 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Pamidronate disodium Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.